Richter Partners with Swiss Biotech on Therapy for Chronic Women’s Health Condition

Gedeon Richter Plc. has signed a strategic research collaboration and option-to-license agreement with Swiss biotechnology company FimmCyte AG. The aim of the collaboration is to jointly develop FimmCyte’s pioneering antibody for the treatment of endometriosis, the pharmaceutical company announced on the Budapest Stock Exchange (BÉT) website on Wednesday.

Under the agreement, the parties will conduct joint research and development activities with the aim of bringing the FMC2 antibody into the clinical development phase. FMC2 is a potentially disease-modifying antibody that could serve as the first therapy to treat the cause of endometriosis. The parties have finalized an exclusive and global license agreement for the future development and commercialization of the antibody. The license will automatically come into effect if Richter exercises its exclusive option right at any time prior to the initiation of the first-in-human clinical study.

Richter stated that

this agreement structure provides a clear and efficient path from preclinical research to global commercialization, eliminating the need for further negotiations on licensing agreements and enabling a rapid transition to clinical development.”

Under the agreement, FimmCyte will be eligible for development and commercial milestone payments with tiered royalties on net sales.

This collaboration combines Richter’s gynecological expertise with FimmCyte’s cutting-edge immunotherapy and proprietary antibody technology to drive innovation and bring to market the first treatment for endometriosis that potentially targets the cause of the disease, they emphasized.

Based on data from the World Health Organization (WHO), endometriosis affects approximately 190 million women worldwide. Despite the widespread nature of the disease, there is currently no causal therapy available; existing treatments are primarily limited to symptom relief, Richter noted.

Via bet.hu, Featured image: Hungary Today

The post Richter Partners with Swiss Biotech on Therapy for Chronic Women’s Health Condition appeared first on Hungary Today.

Source link